The Food and Drug Administration (FDA) has approved extended dosing intervals for Eylea HD ® (aflibercept) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ...
The Food and Drug Administration (FDA) has granted Fast Track designation to CDI-988 for treatment and prophylaxis of norovirus infection.
HealthDay News — Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing abdominal panniculectomy, according to a study published in ...
Confirmatory ZUMA-2 trial data led to full FDA approval of brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.
Improvement in QoL, other PROs seen for those who switched to tirzepatide after not achieving glycemic control on stable dose of dulaglutide.
In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.
Interim data also suggested a strong trend toward improved PFS and OS when evaluating the STRIDE regimen in combination with TACE vs TACE alone.
Incidence of primary end point lower for patients with target LDL level less than 55mg/dL vs less than 70mg/dL.
Postmarketing reports of fatal liver injury associated with avacopan have prompted the FDA to issue a safety alert and recommend new monitoring protocols.
Expanding eligibility for full LIS to include Medicare beneficiaries with incomes between 135 and 150 percent of FPL reduces cost-related medication nonadherence ...
Participants did demonstrate greater proptosis improvement from baseline following the initial high dose period vs after the ...
Supplemental New Drug Application for at-home Igalmi aims to provide a self-administered option for agitation in schizophrenia and bipolar disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results